echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Last month, domestic biopharmaceutical companies reached 6 license-in transactions

    Last month, domestic biopharmaceutical companies reached 6 license-in transactions

    • Last Update: 2022-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
     License-in is a relatively common equity transaction model in the global innovative drug industry in recent years
    .
    This model obtains the rights and interests of product development, production and sales in some countries and regions by agreeing to pay the down payment to the product licensor, according to the "milestones" of the clinical trial progress, sales commissions and other terms

    .
    It is understood that in the past March, domestic biopharmaceutical companies disclosed a number of license-in transactions covering tumor, respiratory system and other fields

    .
    For example, on March 28, 2022, Innovent Bio announced an agreement with Eli Lilly: Innovent Bio obtained the import, sale, promotion and distribution of Cirana (ramucirumab) and Retsevmo (Septitinib) in mainland China Ni) after the approval of the exclusive commercialization rights and granting Innovent Biothe priority negotiation rights to enjoy the future commercialization rights of Pirtobrutinib in mainland China

    .
    According to the agreement, Innovent will pay Eli Lilly a total of US$45 million after the registration of Cirana (ramucirumab) in hepatocellular carcinoma and Retsevmo (septinib) in non-small cell lung cancer.
    down payment

    .
    According to the data, xiranze (ramucirumab) is a treatment option approved by the U.
    S.
    Food and Drug Administration (FDA) for patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma after chemotherapy.
    Approved biomarker-driven therapy for patients with advanced hepatocellular carcinoma (HCC)

    .
    Retsevmo (septinib), a highly selective and potent inhibitor of transfection-rearranged gene (RET), is the first FDA-approved drug specifically for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
    ), adults and children over 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) requiring systemic therapy, and patients with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and radioactive iodine-resistant (if appropriate) inhibitor

    .
    On March 22, 2022, Uray Pharma announced that it has entered into a licensing agreement with Bavarian Nordic, a Danish vaccine company, to acquire the exclusive rights to develop, manufacture and commercialize the Bavarian Nordic Respiratory Syncytial Virus (RSV) vaccine MVA-BN

    .
    Under the terms of the agreement, Bavarian Nordic will receive an upfront payment of $12.
    5 million and is eligible to receive up to $212.
    5 million in future milestone payments that will be triggered upon completion of certain clinical, regulatory and commercial milestones, in addition to There are progressive, double-digit commercialization commissions on future net sales

    .
    The agreement includes clinical development, including support for a registrational Phase 3 trial of MVA-BN RSV in China, which will be conducted separately from another Phase 3 trial that Bavarian Nordic plans to launch in the first half of 2022, Phase 3 trial in support of U.
    S.
    Biologics License Application

    .
    Urui Medicine will bear all costs and responsibilities for the clinical development, registration application and commercialization of the vaccine in the regions covered by the agreement

    .
    Subject to approval from the Chinese regulatory authorities (National Medical Products Administration, NMPA), the company will plan to conduct Phase 1 and Phase 3 trials in China to gain approval of the vaccine

    .
    In addition, on March 21, 2022, Brtiannia Pharmaceuticals signed a license agreement with Brtiannia Pharmaceuticals Ltd, a subsidiary of Germany's STADA Arzneimittel AG, to develop and commercialize its subcutaneous apomorphine in China Exclusive rights for Parkinson's disease

    .
    On March 15, 2022, China Resources Biopharmaceutical Co.
    , Ltd.
    , a subsidiary of China Resources Pharmaceutical, signed a cooperation agreement with Ab Studio Inc.
    of the United States.
    ABS authorized the development and commercialization rights of the ABS-VIR-001 project worldwide to China Resources Biopharmaceuticals.
    China Resources Biopharma will pay certain milestone fees and sales share

    .
    On March 14, 2022, Genting Sunyao announced that it has entered into a licensing agreement with Calliditas Therapeutics AB to develop and commercialize NEFECON in South Korea for the treatment of primary IgA nephropathy (IgAN), expanding its existing portfolio in Greater China and Licensed in Singapore

    .
    The agreement is the company's latest effort to further expand its international business footprint

    .
    On March 9, Sinopharm announced that it had signed a cooperation agreement with Pfizer.

    .
    On March 4, Uray and Swiss company Altamira Therapeutics Ltd announced that they had signed a licensing agreement

    .
    Urui Medicine will acquire the rights to develop and commercialize the latter's product Bentrio in Greater China and South Korea

    .
    "Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone

    .
     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.